Jaguar Health Announces Preliminary Clinical Trial Results for Crofelemer in Short Bowel Syndrome
Reuters
Dec 15
Jaguar Health Announces Preliminary Clinical Trial Results for Crofelemer in Short Bowel Syndrome
Jaguar Health Inc. has announced the submission of an abstract describing preliminary findings from a clinical trial evaluating a novel oral liquid formulation of crofelemer in adult patients with short bowel syndrome with intestinal failure (SBS-IF). The abstract, submitted by an independent investigator at a leading SBS-IF treatment institution, is under consideration for presentation at the Digestive Disease Week® conference scheduled for May 2-5, 2026. Results from the study have not yet been presented. Crofelemer has received Orphan Drug Designation from both the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of SBS and microvillus inclusion disease (MVID). Jaguar Health and its subsidiary Napo Pharmaceuticals are also conducting additional clinical trials of crofelemer in both adult and pediatric patient populations with intestinal failure.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1117305) on December 15, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.